http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
소화성 위장질환에 사용하는 Cimetidine , Ranitidine , Proglumide 및 Clebopride 의 면역반응조절
김대곤(Dae Ghon Kim),허영상(Yeong Sang Heo),안관용(Kwan Yong Ahn),이용기(Yong Gi Lee),안득수(Deuk Su Ahn) 대한내과학회 1987 대한내과학회지 Vol.33 No.1
N/A It has been reported that among many drugs used for the treatment of peptic gastrointestinal disorder, a few drugs exerts a variety of modulating effects on immune responsiveness. This study was undertaken to investigate the effect of four of the drugs on immune response of mice to sheep red blood cells (SRBC). Four drugs used in this experiment are cimetidine, a imidazole derivative of histamine type 2 (H₂) receptor antagonist; ranitidine, a furan derivative of H₂, antagonist; proglumide, a gastrin antagonist; and clebopride, a dopamine antagonist. Mice were pretreated with daily oral administration of varying concentration of each drugs for 30 days and were immunized with 10(8) SRBC. Each mouse was challenged 4 days after the sensitization, Immune response were evaluated by measuring footpad swelling reaction at 3 hr (Arthus reaction) and 24hr (delayed type hypersensitivity, DTH) after challenge, rosette forming reaction, hemagglutinin (HA) and hemolysine (HE) titers to SRBC. The pretreatment of mice with cimetidine inhibited Arthus and rosette forming reactions, but enhanced DTH to SRBC. The pretreatment of mice with proglumide suppressed both DTH and rosette forming reaction. The pretreatment of mice with clebopride enhanced DTH, but decreased rosette forming reaction. In contrast to cellular immune response, there was not any significant difference between the drug treated and untreated control groups in HA and HE reactions. These results suggest that cimetidine, ranitidine and clebopride enhance cellular immune response, but proglumide suppress the above response and all of the drugs do not significantly change the humoral immune response.
Clinical Studies on Sulbactam/Ampicillin in Internal Medicine
Ahn, Deuk Soo,Kim, Dae Ghon,Kim, Jin Hong,Ahn, Kwan Yong 의과학연구소 1987 全北醫大論文集 Vol.11 No.3
Sulbactam(sodium penicillinate sulfone, CP 45, 899)은 beta-lactamase inhibitor로서 그 자체는 항균 작용을 거의 갖지 않으나 ampicillin과 병합 투여 했을 때 ampicillin의 항균범위를 신장시킨다. 즉 이 병합 요법은 ampicillin 내성 staphylococcus aureus, Haemophilus influenza, anaerobic bacteria, Escherichia coli등의 많은 다른 균주들에 효과가 있다고 한다. 1985년 3월에서 1986년 8월까지 전북의대 부속병원 내과 입원 환자 25명을 대상으로 sulbactam/ampicillin 병합 요법을 고찰하였다. 처음부터 이 병합 요법을 실시하였거나 또는 다른 항생제가 무효하다고 판정된 경우에만 투여하였으며 환자군의 분류는 폐염 9예, 신우신염 7예, 세균성 이질 2예였다. 임상적 고찰 및 반응에 근거한 이 병합 요법의 효과는 96%였으며 분리균주의 약제 감수성은 77%를 보였다. Sulbactam/ampicillin 병합 치료 중 혈액검사, 간기능검사, 혈청화학검사 등의 이상 소견은 발견되지 않았으며 따라서 이 병합 요법은 중증 감염증인 폐염, 장열, 신우신염 및 세균성 이질 등의 치료에 우수한 효과가 있음을 알 수 있었다. (Key words : sulbactam, ampicillin, 병합요법)
기능성 위장관 질환의 증상에 대한 Clebopride의 치료효과
이남심,안관용,안득수 전북대학교 의과학연구소 1985 全北醫大論文集 Vol.9 No.3
To evaluate the effect of clebopride on the symptoms of various functional G-Ⅰ disease, we observed improvement of the individual clinical symptoms and the side effects after administration of the drug in the 43 cases of patients with gastric ptosis, chronic gastritis, cascade stomach, iriitable bowel syndrome and alimentary tract neurosis, etc. in the department of Internal Medicine of Chonbuk National University Hospital from Mar. 1984 to Aug. 1984. Gastric empting times(G.E.T.'s, T½) of solid phase and serum gastrin levels were also measured with radioisotope(^99^mTc) and radioimmunoassay. The results were as follows ; 1) In the 43 cases of functional G-Ⅰ tract disease, symptomatic improvement were observed in cascade stomach(70%), chronic gastritis(65%), gastric ptosis(60%). 2) The G.E.T.(T½) of the solid phase measured by using the ^99^mTc isotope were within normal range(77.1sec) in 8 cases. There was no significant difference in the improvement of the symptoms between these 8 cases and normal control. 3) In thr group of the patients with severs synptoms in association with low gastrin levels, good to symtomatic improvement were observed in 85.3% effect. 4) Individual symptoms improved by the administratio of the drug included epigastric fullness and discomfort, indigestion, nausea, hunger pain, hypertonia and substernal discomfor. 5) Side effects of the drug observed were not specific, but drowsy, lassitude, mild headache, reappearance of pre-existing symptoms after withdrawal of the drug were observed.
姜聲貴,安官鎔,朴聖光 전북대학교 의과학연구소 1983 全北醫大論文集 Vol.7 No.2
The patients with post-traumatic renal scarring are usually asymptomatic, although they may be hypertensive. They are frequently unaware of renal injury and first seek care for evaluation of hypertension or for unrelated problems requiring intravenous pyelography. Authors experienced a patient who had developed a hypertension after a removal operation of perirenal hematoma caused by fall-down injury and report a case with a review of literature.
폐결핵환자에서 혈청 Angiotensin-Converting-Enzyme(ACE) 활성도의 변동에 관한 연구
최은영,이양근,유관희,안관용,오강열,박성희 대한내과학회 1986 대한내과학회지 Vol.30 No.1
Angiotensin converting enzyme which is thought to be originated from the epitheloid cells with area of series phagocytosis reported to be inreasced in sarcoidosis, Gaucher`s disease, chronic renal failure, diabetes mellitus and leprosy, The serum ACE activity was assayed spectrophotometrically in 28 pulmonary tuberculosis patients and 13 bronchial asthma patients to investigate ACE activity can be used as an index of tuberculosis activity. The results were as follows: 1) The serum ACE level was higher in patients with active pulmonary tuberculosis (3.4348±3.2079) than in normal control group(1.4026±2.0034) (P0.05). 2) On cheat roentgenographic findings, the serum ACE level was higher in patients of active minimal pulmonary tubereulosis than those of the moderate advanced pulmonary tuberculosis. 3) Forced vital capacity showed significantly strong negative correlation with the serum ACE level(r=-0.4133) while no significant correlation was found between serum ACE level and other pulmonary diseases. It can beuggested that activity of serum ACE is useful parameter to indicate activity E. progress of pulmonary tuberculosis.